ASX:ANP Antisense Therapeutics (ANP) Stock Price, News & Analysis Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.32 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield4.58%Price TargetN/A Stock AnalysisStock Analysis Get Antisense Therapeutics alerts: Email Address Ad DTIWeird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?Click here to see the 10 best trades upcoming in 2024 for FREE About Antisense Therapeutics Stock (ASX:ANP)Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia.Read More Ad DTIWeird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?Click here to see the 10 best trades upcoming in 2024 for FREE ANP Stock News HeadlinesSeptember 2, 2024 | markets.businessinsider.comMorgans Sticks to Its Buy Rating for Antisense Therapeutics Limited (ATHJF)August 28, 2024 | reuters.comIT outages ground flights at second largest Dutch airportSeptember 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?August 28, 2024 | msn.comAir traffic halts at Netherlands' Eindhoven Airport after 'disruption', ANP reportsJuly 19, 2024 | msn.com‘Ban military interference, not political parties,’ says ANP’s Aimal WaliJuly 19, 2024 | msn.comANP's Asfandyar Wali Khan describes govt's intention to ban PTI as 'undemocratic'April 15, 2024 | finance.yahoo.comAnpario plc's (LON:ANP) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?April 5, 2024 | msn.comScoPo’s (actually Wilkie’s) Powerplays: Blinklab soars 32.5% in first healthcare IPO of 2024September 16, 2024 | DTI (Ad)Weird phenomenon on AMZN stockWhat would you do if you knew that you could have bought Amazon on May 25th every year and walked away with a win?April 1, 2024 | msn.comANP improves net income to MAD 105 mln in 2023April 1, 2024 | msn.comANP slams Qaiser's advice to snap ties with govtMarch 31, 2024 | ca.news.yahoo.comDutch nightclub hostage drama ends peacefully with arrest of suspectMarch 31, 2024 | msn.comDutch nightclub hostage drama ends peacefullyMarch 20, 2024 | reuters.comDutch court finds KLM ads were misleading in 'greenwashing' suit -ANPMarch 6, 2024 | msn.comANP calls for judicial commission to probe rigging in Feb 8 pollsMarch 1, 2024 | msn.comJUI-F, ANP shun elections of top officesFebruary 29, 2024 | msn.comWon't participate in election to posts of president, PM, speaker: ANP chiefFebruary 13, 2024 | msn.comANP's Aimal Wali rejects polls resultsSee More Headlines Receive ANP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antisense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2019Today9/16/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryConsumer Goods Current SymbolASX:ANP CUSIPN/A CIKN/A Webwww.antisense.com.au Phone61 3 9827 8999FaxN/AEmployees5,500Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,380,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.14% Return on Assets-41.69% Debt Debt-to-Equity Ratio1.42 Current Ratio4.51 Quick Ratio18.16 Sales & Book Value Annual Sales$1.58 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow4.18 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares901,550,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.06 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. James Garner B.Sc (Hons) (Age 50)B.Sc., M.A., M.A.I.C.D., M.B.A., MBA, CEO, MD & Director Comp: $9.77kMr. Phillip Allen Hains BBus(Acc) (Age 64)C.A., M.B.A., CFO & Joint Company Secretary Comp: $160.28kDr. Anthony FilippisChief Operating OfficerMs. Alicia MellorsJoint Company SecretaryKey Competitors27557 (MBC.TO)TSE:MBCAEA-Bridges ImpactOTCMKTS:IMPXUBiologix HairOTCMKTS:BLGXCauldron EnergyASX:CXUColgate-PalmoliveTSE:CLView All CompetitorsInsidersJames GarnerBought 100,000 shares on 11/17/2023Total: $6,100.00 ($0.06/share)Ben PriceBought 400,000 shares on 9/26/2023Total: $28,400.00 ($0.07/share) ANP Stock Analysis - Frequently Asked Questions How were Antisense Therapeutics' earnings last quarter? Antisense Therapeutics Limited (ASX:ANP) issued its earnings results on Wednesday, February, 27th. The company reported $0.00 EPS for the quarter. What other stocks do shareholders of Antisense Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN). This page (ASX:ANP) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antisense Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Antisense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.